These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

241 related items for PubMed ID: 17069803

  • 61.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 62. Lupus erythematosus profundus (lupus panniculitis) induced by interferon-beta in a multiple sclerosis patient.
    Gono T, Matsuda M, Shimojima Y, Kaneko K, Murata H, Ikeda S.
    J Clin Neurosci; 2007 Oct; 14(10):997-1000. PubMed ID: 17669654
    [Abstract] [Full Text] [Related]

  • 63. Will public health survive QALYs?
    Heller JG.
    Can J Clin Pharmacol; 2002 Oct; 9(1):5-6. PubMed ID: 11919640
    [No Abstract] [Full Text] [Related]

  • 64. Interferon-beta induces brain-derived neurotrophic factor in peripheral blood mononuclear cells of multiple sclerosis patients.
    Lalive PH, Kantengwa S, Benkhoucha M, Juillard C, Chofflon M.
    J Neuroimmunol; 2008 Jul 15; 197(2):147-51. PubMed ID: 18555540
    [Abstract] [Full Text] [Related]

  • 65. Multiple sclerosis: interferon beta for some serious forms.
    Prescrire Int; 2007 Dec 15; 16(92):252-7. PubMed ID: 18092425
    [Abstract] [Full Text] [Related]

  • 66. Solving the MS puzzle.
    Hobson K.
    US News World Rep; 2002 Oct 07; 133(13):60-2. PubMed ID: 12375480
    [No Abstract] [Full Text] [Related]

  • 67. Interferon beta, progressive MS, and brain atrophy.
    Chaudhuri A.
    Lancet Neurol; 2005 Apr 07; 4(4):208-9. PubMed ID: 15778099
    [No Abstract] [Full Text] [Related]

  • 68. Concepts of induction and escalation therapy in multiple sclerosis.
    Rieckmann P.
    J Neurol Sci; 2009 Feb 01; 277 Suppl 1():S42-5. PubMed ID: 19200866
    [Abstract] [Full Text] [Related]

  • 69. Neutralizing antibodies to interferon.
    Noronha A.
    Neurology; 2007 Jun 12; 68(24 Suppl 4):S16-22. PubMed ID: 17562846
    [Abstract] [Full Text] [Related]

  • 70. Neurodegeneration and neuroprotection in multiple sclerosis.
    Stangel M.
    Curr Pharm Des; 2012 Jun 12; 18(29):4471-4. PubMed ID: 22612743
    [Abstract] [Full Text] [Related]

  • 71. Immunogenicity and tolerability of an investigational formulation of interferon-beta1a: 24- and 48-week interim analyses of a 2-year, single-arm, historically controlled, phase IIIb study in adults with multiple sclerosis.
    Giovannoni G, Barbarash O, Casset-Semanaz F, Jaber A, King J, Metz L, Pardo G, Simsarian J, Sørensen PS, Stubinski B, RNF Study Group.
    Clin Ther; 2007 Jun 12; 29(6):1128-45. PubMed ID: 17692727
    [Abstract] [Full Text] [Related]

  • 72. Effect of anti-IFN{beta} antibodies on MRI lesions of MS patients in the BECOME study.
    Pachner AR, Cadavid D, Wolansky L, Skurnick J.
    Neurology; 2009 Nov 03; 73(18):1485-92. PubMed ID: 19884576
    [Abstract] [Full Text] [Related]

  • 73. [Interferon β].
    Matsushita T.
    Nihon Rinsho; 2015 Sep 03; 73 Suppl 7():196-204. PubMed ID: 26480700
    [No Abstract] [Full Text] [Related]

  • 74. Biomarkers for interferon response in MS: are we there yet?
    Rudick RA, Ransohoff RM.
    Neurology; 2008 Mar 25; 70(13 Pt 2):1069-70. PubMed ID: 18362268
    [No Abstract] [Full Text] [Related]

  • 75. Quinpramine: revival of old anti-inflammatory principles in multiple sclerosis?
    Haghikia A, Gold R.
    Exp Neurol; 2009 Jun 25; 217(2):240-1. PubMed ID: 19361499
    [No Abstract] [Full Text] [Related]

  • 76. Interferon beta-associated retinopathy in patients treated for multiple sclerosis.
    Folden DV, Lee MS, Ryan EH.
    Neurology; 2008 Mar 25; 70(13 Pt 2):1153-5. PubMed ID: 18362275
    [No Abstract] [Full Text] [Related]

  • 77. [Therapies in multiple sclerosis].
    Kesselring J.
    Praxis (Bern 1994); 2013 Aug 21; 102(17):1061-7. PubMed ID: 23965719
    [Abstract] [Full Text] [Related]

  • 78. Modern multiple sclerosis treatment - what is approved, what is on the horizon.
    Pilz G, Wipfler P, Ladurner G, Kraus J.
    Drug Discov Today; 2008 Dec 21; 13(23-24):1013-25. PubMed ID: 18775508
    [Abstract] [Full Text] [Related]

  • 79. T-helper 17 cells expand in multiple sclerosis and are inhibited by interferon-beta.
    Durelli L, Conti L, Clerico M, Boselli D, Contessa G, Ripellino P, Ferrero B, Eid P, Novelli F.
    Ann Neurol; 2009 May 21; 65(5):499-509. PubMed ID: 19475668
    [Abstract] [Full Text] [Related]

  • 80. Elevation of matrix metalloproteinases (MMPs) in multiple sclerosis and impact of immunomodulators.
    Yong VW, Zabad RK, Agrawal S, Goncalves Dasilva A, Metz LM.
    J Neurol Sci; 2007 Aug 15; 259(1-2):79-84. PubMed ID: 17382965
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.